The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

It's another wild twist in the story of Galapagos, a company that has been around for more than 25 years but has yet to get a ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European ...

The Most Favored Nations directive would allow drugmakers to directly sell their products to patients at a lower cost, ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

While industry groups decried the Trump administration’s new drug pricing order, analysts say it lacked details and the teeth ...

The package revives President Donald Trump’s much-maligned Most Favored Nations rule but goes further into the private ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

Roche committed $50 billion in U.S. manufacturing funds, with which it will construct at least four new facilities.

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...